AstraZeneca says vaccine 80% effective for elderly, no blood clot risk

AstraZeneca’s COVID-19 vaccine is 80% effective at preventing the disease in the elderly and does not increase the risk of blood clots, the biotech firm said, following its US phase 3 efficiency trials.

It was 79% effective at preventing symptomatic COVID-19 in the overall population and 100% effective at preventing severe disease and hospitalization.

Several countries had advised against administering the jab to older people due to a lack of data among elderly participants in previous trials. Earlier in March, several countries also paused use of the AstraZeneca shot over fears it may cause blood clots.

The US phase 3 trial of the vaccine developed by AstraZeneca and Oxford University involved 32,449 participants, with two thirds receiving the jab.

Around 20% were 65 or older, and 60% had health conditions associated with a higher risk of severe COVID-19, such as diabetes, severe obesity or cardiac disease.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.